Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | EP300 | Q09472 | 1/20 | 0.46 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | PLAT | P00750 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4074725 | 0.86 | IDO1 (0.53) | IDO1EP300KAT8LTA4HMAPK14 | |
| SCHEMBL367776 | 0.86 | CYP11B1 (0.48) | ABCB1IDO1EP300KAT8LTA4H | |
| SCHEMBL6175794 | 0.83 | IDO1 (0.44) | ABCB1IDO1EP300KAT8LTA4H | |
| SCHEMBL31086650 | 0.83 | IDO1 (0.44) | IDO1EP300KAT8LTA4HMAPK14 | |
| SCHEMBL1979771 | 0.83 | IDO1 (0.44) | IDO1EP300KAT8LTA4HMAPK14 | |
| SCHEMBL18567053 | 0.81 | ABCB1 (0.48) | ABCB1HSD17B10ALDH1A1SMN1; SMN2PLAU | |
| SCHEMBL13393569 | 0.80 | AOC1 (0.45) | IDO1EP300KAT8MAPK14PLAU | |
| SCHEMBL14988643 | 0.80 | APP (0.64) | ABCB1LTA4HMAPK14HSD17B10ALDH1A1 | |
| SCHEMBL4087525 | 0.78 | MAPT (0.55) | LTA4HMAPK14HSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL22898278 | 0.78 | PLAU (0.40) | IDO1EP300KAT8LTA4HMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147104-B1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMA (US) | 2012-03-14 | — | — | EP | disclosed |
| US-8114873-B2 | 1,4-disubstituted naphthalenes as inhibitors of p38 map kinase | ARQULE, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100311754-A1 | 1,4-Disubstituted Naphthalenes as Inhibitors of P38 Map Kinase | ARQULE, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-7829560-B2 | 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase | ARQULE, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20080032967-A1 | 1,4-Disubstituted Naphthalenes as Inhibitors of P38 Map Kinase | ARQULE, INC. | 2008-02-07 | — | — | US | disclosed |
| WO-2006010082-A1 | 1,4-DISUBSTITUTED NAPHTALENES AS INHIBITORS OF P38 MAP KINASE | ARQULE, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| EP-1200411-B1 | PROCESS FOR SYNTHESIS OF HETEROARYL-SUBSTITUTED UREA COMPOUNDS | BOEHRINGER INGELHEIM PHARMA (US) | 2005-12-14 | — | — | EP | disclosed |
| EP-1163236-B1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMA (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6894173-B2 | Intermediates useful for synthesis of heteroaryl-substituted urea compounds, and processes of making same | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-05-17 | — | — | US | disclosed |
| US-6835832-B2 | Catalytic hydrogenation | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-12-28 | — | — | US | disclosed |
| US-20030166930-A1 | Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | US | disclosed |
| WO-2003068223-A1 | ARYL UREAS WITH RAF KINASE AND ANGIOGENESIS INHIBITING ACTIVITY | BAYER CORPORATION (US) | 2003-08-21 | — | — | WO | disclosed |
| US-6583282-B1 | Formation of a urea by reacting an aromatic carbamate with a aromatic amine | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-06-24 | — | — | US | disclosed |
| US-20030109703-A1 | Polymorph and process for preparing same | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-06-12 | — | — | US | disclosed |
| US-6476023-B1 | Aromatic heterocyclic compounds as anti-inflammatory agents | BOEHRINGEN INGELHEIM PHARMACEUTICALS, INC. | 2002-11-05 | — | — | US | disclosed |
| EP-1200411-A2 | NOVEL PROCESS FOR SYNTHESIS OF HETEROARYL-SUBSTITUTED UREA COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-05-02 | — | — | EP | disclosed |
| EP-1163236-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2001-12-19 | — | — | EP | disclosed |
| US-6297381-B1 | INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES SUCH AS INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR, UREAS OR THIOUREAS SUBSTITUTED BY A PYRROLE OR THIOPHENE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-10-02 | — | — | US | disclosed |
| WO-2001004115-A2 | NOVEL PROCESS FOR SYNTHESIS OF HETEROARYL-SUBSTITUTED UREA COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-01-18 | — | — | WO | disclosed |
| WO-2000055152-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311754-A1 | 1,4-Disubstituted Naphthalenes as Inhibitors of P38 Map Kinase | MAPK1, MAPK7, MAP3K1 | ABCB1 2600/4885IDO1 698/4885EP300 1073/4885 |
| US-20030109703-A1 | Polymorph and process for preparing same | UGT1A1, CYP1A1, CYP1B1 | ABCB1 280/4885IDO1 426/4885EP300 1419/4885 |
| US-20030166930-A1 | Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents | URB2, UGT1A1, PURB | ABCB1 1672/4885IDO1 210/4885EP300 696/4885 |
| US-20080032967-A1 | 1,4-Disubstituted Naphthalenes as Inhibitors of P38 Map Kinase | MAPK1, MAPK8, MAPK4 | ABCB1 2636/4885IDO1 1252/4885EP300 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.